1 / 12

Tirofiban Meta-Analysis

Tirofiban Meta-Analysis. Tirofiban Meta-Analysis: Efficacy at 30 Days. Administration Pre-Angiography (Upstream) and PCI Likely (Downstream). P <.00001. % of Patients. P =.001. *12  g/kg bolus over 30 min (upstream) and 10  g/kg bolus & 25  g/kg bolus (downstream).

sawyer
Download Presentation

Tirofiban Meta-Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tirofiban Meta-Analysis

  2. Tirofiban Meta-Analysis: Efficacy at 30 Days Administration Pre-Angiography (Upstream) and PCI Likely (Downstream) P<.00001 % of Patients P=.001 *12 g/kg bolus over 30 min (upstream) and 10g/kg bolus & 25 g/kg bolus (downstream) Valgimigli M, et al. EHJ. Published online September 14, 2009.

  3. Tirofiban Meta-Analysis: Death or MI at 30 Days Administration Pre-Angiography (Upstream) and PCI Likely (Downstream) P=.002 P=.006 % of Patients P=.07 m m m *Bolus over 30 Minutes (Upstream) During PCI (Downstream) Valgimigli M, et al. EHJ. Published online September 14, 2009.

  4. Tirofiban Meta-Analysis: Mortality at 30 Days Administration Pre-Angiography (Upstream) and PCI Likely (Downstream) P=.01 % of Patients P=.07 P=.25 m m m *Bolus over 30 Minutes (Upstream) During PCI (Downstream) Valgimigli M, et al. EHJ. Published online September 14, 2009.

  5. Tirofiban Meta-Analysis: Safety at 30 Days Administration Pre-Angiography (Upstream) and PCI Likely (Downstream) P=.002 % of Patients P=.24 *12 g/kg bolus over 30 min (upstream) and 10g/kg bolus & 25 g/kg bolus (downstream) Valgimigli M, et al. EHJ. Published online September 14, 2009.

  6. Tirofiban Meta-Analysis: Efficacy at 30 Days Administration when PCI Likely or Planned (Downstream) P=.11 % of Patients P=.70 *10g/kg bolus & 25 g/kg bolus (downstream) Valgimigli M, et al. EHJ. Published online September 14, 2009.

  7. Tirofiban Meta-Analysis: Death or MI at 30 Days Administration when PCI Likely or Planned (Downstream) P=.03 P=.54 % of Patients m m *10g/kg bolus & 25 g/kg bolus (downstream) Valgimigli M, et al. EHJ. Published online September 14, 2009.

  8. Tirofiban Meta-Analysis: Mortality at 30 Days Administration when PCI Likely or Planned (Downstream) P=.38 % of Patients P=.65 m m *10g/kg bolus & 25 g/kg bolus (downstream) Valgimigli M, et al. EHJ. Published online September 14, 2009.

  9. Tirofiban Meta-Analysis: Safety at 30 Days Administration when PCI Likely or Planned (Downstream) P<.001 % of Patients P=.04 *10g/kg bolus & 25 g/kg bolus (downstream) Valgimigli M, et al. EHJ. Published online September 14, 2009.

  10. Tirofiban Meta-Analysis: Death or MIat Long-Term Follow Up Administration when PCI Likely or Planned (Downstream) P=.34 P=.10 P=.35 % of Patients m m *10g/kg bolus & 25 g/kg bolus (downstream) Valgimigli M, et al. EHJ. Published online September 14, 2009.

  11. Tirofiban Meta-Analysis: Key Points • Tirofiban when compared with placebo or bivalirudin at 30 days • Significantly reduced mortality and the composite of death or MI • 12 mg/kg Bolus (label) administered over 30 minutes (Upstream) • Significantly reduced mortality and the composite of death or MI • 25 mg/kg Bolus (Downstream) • Significantly reduced the composite of death or MI • Significantly increased TIMI minor bleeding and thrombocytopenia • Demonstrated no significant difference in TIMI major bleeding

  12. Tirofiban Meta-Analysis: Key Points • Tirofiban when compared with abciximab (Downstream only) • Demonstrated no significant difference in mortality and the composite of death or MI at 30 days or long-term follow up • 10 mg/kg Bolus – TARGET Trial (Downstream) • Demonstrated a significant increase in the composite of death or MI at 30 days, which was lost at long-term follow up • Demonstrated no significant difference in mortality at 30 days or at long-term follow up • 25 mg/kg Bolus (Downstream) • Demonstrated no significant difference in mortality or the composite of death or MI at 30 days or at long-term follow up • Significantly reduced TIMI minor bleeding and thrombocytopenia • Demonstrated no significant difference in TIMI major bleeding

More Related